CNXU · Conexeu Sciences Inc.

900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 650,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.

The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.

The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.

900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 400,000 Performance Warrants have vested. The remainder of the Performance Warrants will vest and be exercisable upon the following milestone events: (i) 250,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of >$80,000,000 in the currency of the recognized stock exchange in North America on which the shares of common stock are listed; and (ii) 250,000 Performance Warrants upon the Issuer's submitting a 510(k) application to the United States Food and Drug Administration.

The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. The Performance Warrants will vest and be exercisable upon the following milestone events: (i) 500,000 Performance Warrants upon the Issuer's shares of common stock being listed on a recognized stock exchange in North America, which have vested; (ii) 500,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed; and (iii) 500,000 Performance Warrants upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

The reported shares were issued to the Reporting Person at a deemed price of $4.00 per share for total compensation of $44,700 owing to the Reporting Person for services rendered to the issuer, which is payable in shares. No price was paid for the shares.